An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.
By H. Zou, Qiuhua Li, Joseph H. Lee, M. Arango, S. McDonnell, S. Yamazaki, T. Koudriakova, G. Alton, J. Cui, P. Kung and 5 more. Cancer Research, 2007
650 citations recorded by the source corpus.
Subfields: Hepatology, Molecular Biology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/38eb0277f5b679546421a74c25ff38bd4334a441
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Pathology and Forensic Medicine
Citations in the corpus
- The anaplastic lymphoma kinase in the pathogenesis of cancer (2008, background): “Also, a recently described inhibitor of MET and ALK (PF-2341066) was orally bioavailable and showed marked cytoreductive anti-tumour activity in several tumour model”
- Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma (2007, methodology): “At concentrations >300 nmol/L, PF-2341066 was shown to exhibit some inhibitory activity against related receptor tyrosine kinases, including RON, Axl, and TrkA and TrkB (26).”
- Pre-existence and clonal selection of MET amplification in EGFR mutant NSCLC (2010, methodology): “We used both a tool compound PHA-665,752 and the MET inhibitor PF02341066 currently undergoing clinical development (Figure 1C, upper panel; data not shown) (Zou et al., 2007).”